Product Program year 2019 Source: CMS Open Payments

Yescarta

Drug Onc

NDC 71287-119-02

Open in the dashboard

General payments

$1,643,755

2,217 payments

Research payments

$2,819,173

328 payments

Through program year 2019, $1,643,755 in general payments and $2,819,173 in research payments were reported against Yescarta (Onc).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $1,643,755 2,217
2019 Research $2,819,173 328

Breakdown

Who paid General payments · program year 2019
  1. Kite Pharma, Inc. $1,512,180 2,115 payments
  2. Gilead Sciences, Inc. $131,575 102 payments
Top recipients General payments · program year 2019
  1. Javier Munoz Hematology & Oncology · Phoenix, AZ $154,782 9% · 173 payments
  2. Ahmed Galal Hematology · Morristown, NJ $138,113 8% · 102 payments
  3. Ran Reshef Hematology · New York, NY $129,953 8% · 124 payments
  4. Mehrdad Abedi Hematology & Oncology · Sacramento, CA $68,191 4% · 42 payments
  5. Brian Hill Hematology & Oncology · Cleveland, OH $56,449 3% · 22 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Hematology & Oncology Internal Medicine $924,724 58% · 416 practitioners
  2. Hematology Internal Medicine $356,019 22% · 48 practitioners
  3. Medical Oncology Internal Medicine $214,741 13% · 109 practitioners
  4. Pediatric Hematology-Oncology Pediatrics $64,136 4% · 7 practitioners
  5. Occupational Medicine Preventive Medicine $12,080 <1% · 1 practitioner

The top 5 of 31 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Texas $225,356 14% · 57 recipients
  2. Pennsylvania $161,978 10% · 44 recipients
  3. Arizona $155,132 9% · 12 recipients
  4. South Dakota $144,286 9% · 2 recipients
  5. California $138,914 8% · 80 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

2,217 general · 328 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record